Davis Joseph was awarded the 2025 Ciechanover International Biology Award at the Sustainability through Science and Technology Summit 2025 (FLOGEN SIPS 2025) in Cebu, Philippines, for a breakthrough cancer discovery proposing organ-agnostic treatment strategies. His work identifies three universal cancer types based on dysfunctions in p14ARF/p53, DINO lncRNA, and MDM2 activity, and introduces a universal apoptosis network flowsheet built from the analysis of 174 scientific publications. The discovery supports a unified therapeutic framework for treating cancers regardless of the organ in which they originate and is presented as an example of Sustainable Medicine under the FLOGEN Sustainability Framework.

Temporomandibular joint (TMJ) pain is associated with disrupted gut microbiome metabolites. Researchers reveal that butyrate, administered as tributyrin, alleviates pain by restoring histone acetylation and reversing gene regulatory changes in the brain. The team identified key genes involved in pain modulation, such as Nop14 using a mouse model as well as single-cell multi-omics sequencing. Targeting butyrate-related epigenetic pathways may offer a promising non-opioid strategy for treating TMJ pain.

Recent decades have witnessed unprecedented scientific growth driven by the convergence of clinical medicine, life sciences, information technology, materials science, and quantum computing. Landmark achievements such as the Human Genome Project, CRISPR-Cas9 gene editing, and multi-omics technologies have provided deep insights into human biology. Meanwhile, artificial intelligence, wearable devices, big data analytics, and the Internet of Medical Things have revolutionized medical data processing, clinical decision-making, and remote patient monitoring. These advances are accelerating drug development, digitalizing public health systems, and transforming medical diagnosis from experience-based practice to AI-augmented precision detection. Personalized medicine now benefits millions of cancer patients, while regenerative medicine offers new solutions for tissue and organ repair. Against this backdrop, the inaugural issue of MedScience is launched as the new identity of the Chinese Academy of Engineering medical journal. Originally established as Frontiers of Medicine in China in 2007 and renamed Frontiers of Medicine in 2011, the journal has achieved indexing in Scopus, PubMed/Medline, and SCI-E. The name MedScience embodies a commitment to both medical service and scientific rigor. The journal will focus on emerging fields including cell and gene therapy, AI-driven drug discovery, organoids, precision medicine, and environmental health, aiming to serve as a dynamic international platform that transcends disciplinary boundaries and contributes to global human health advancement.